EWTXEdgewise Therapeutics, Inc.
$39.02+174% 1Y
$39.02
$14.7052 weeks$46.97
EWTX in its own filings
EWTX's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
95
Events found in the filings · across 419 filings · the record starts in 2021
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 8-K
- Record starts
- Jan 12, 2021
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Delisting notice / listing-rule failure2 occurrences
- 2023-07-14
- SEC comment-letter activity6 occurrences
- 2022-05-03
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Edgewise Therapeutics Reports Second Quarter.Earnings release · press release
- Jul 16, 2026On May 31, 2026, Edgewise Therapeutics, Inc. (“Edgewise”Material event (exhibits only) · press release
- Jul 13, 2026On July 10, 2026, Edgewise Therapeutics, Inc. (the “Company”) completed the previously announced acquisition of the Company’s sevasemten compound and certain other related assets collectively constituting the Company’s muscular dystrophy program (the “Program”) by Servier Pharmaceuticals LLC and Les Laboratoires …Acquisition or disposition completed · Form 8-K
- Jun 1, 2026On June 1, 2026, Edgewise Therapeutics, Inc., (the “Company”) announced its entry into an Asset Purchase Agreement (the “Agreement”) with Servier Pharmaceuticals LLC and Les Laboratoires Servier (together, the “Buyers”) on May 31, 2026.Material agreement entered · Form 8-K
- May 7, 2026Edgewise Therapeutics Reports First Quarter.Earnings release · press release
- Feb 26, 2026Edgewise Therapeutics Reports Fourth Quarter.Earnings release · press release
- Nov 20, 2025Election of Director On November 19, 2025, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Christopher Martin to serve as a Class I director, with a term expiring at the Company’s 2028 annual meeting of stockholders.Director or officer change · Form 8-K
- Nov 10, 2025On November 10, 2025, Edgewise Therapeutics, Inc. (the “Company”) announced the appointment of Michael Nofi as the Company’s Chief Financial Officer, effective November 10, 2025.Director or officer change · Form 8-K
- Nov 6, 2025Edgewise Therapeutics Reports Third Quarter.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…